Key Takeaways
Citi reiterated its Neutral rating on Novo Nordisk (NYSE: NVO) but lifted its price target to DKK290, signaling a cautious outlook despite a strong launch for the company's oral version of its Wegovy weight-loss drug and first-quarter results that beat expectations.
The bank's neutral stance stems from concerns about future profitability, even as it holds a more optimistic view on the new pill's potential than the market average. "The neutral stance is maintained on two principal concerns: Citi's 2027 earnings per share estimate remains 7% below consensus... and significant uncertainty persists over mid-to-long-term pricing dynamics and competitive intensity in the obesity market," the bank noted.
Citi raised its peak sales estimate for the Wegovy pill to $8 billion, compared to a market consensus of $7.1 billion. For 2026, the bank forecasts sales of $2.7 billion, a full $1 billion ahead of the $1.7 billion consensus. However, these higher sales estimates did not translate into a more bullish rating due to expected pressure on pricing and margins from competitors and policies like most-favoured-nation pricing in diabetes.
The analysis highlights a central tension for Novo Nordisk: impressive near-term sales momentum against the backdrop of a rapidly intensifying competitive landscape. While the launch of the oral GLP-1 has been successful and has not been impacted by rivals like Foundayo, Citi's caution suggests the market may be underestimating long-term margin compression.
This view implies that while Novo Nordisk is executing well on its oral drug strategy, investors should closely monitor competitive developments and pricing trends that could affect future profitability. The next major development for the company will be the progression of its next-generation oral obesity treatment, zenagamtide (also known as amycretin), into phase three trials.
This article is for informational purposes only and does not constitute investment advice.
